The effect of immunotherapy on cross-reactivity between house dust mite and other allergens in house dust mite -sensitized patients with allergic rhinitis
机构：[1]Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China临床科室耳鼻咽喉-头颈外科首都医科大学附属北京同仁医院首都医科大学附属同仁医院[2]Beijing Key Laboratory of Nasal Disease, Beijing Institute of Otolaryngology, Beijing, China研究所耳鼻咽喉科研究所首都医科大学附属北京同仁医院首都医科大学附属同仁医院
Introduction House dust mite (HDM) is a main perennial allergen causing allergic rhinitis (AR). It has been shown that HDM cross-reacts with a variety of other allergens. Presently, allergen-specific immunotherapy (AIT) is an effective way for management of mono-sensitized HDM+ AR patients. However, management approaches to polysensitized HDM-sensitized AR patients are not standardized yet. Area covered This article reviews the data available in the literature for cross-reactivity between HDM and inhalant or food allergens, the diagnosis of cross-reactivity in HDM-sensitized AR patients, and the effect of immunotherapy on cross-reactivity in HDM-sensitized AR patients; which may help to develop effective therapeutic strategies for management of polysensitized HDM-sensitized AR patients in the future. Expert opinion Pan-allergen proteins such as tropomyosin, arginine kinase (AK), glutathione S-transferase (GST), and hemocyanin are responsible for cross-reactivity between HDM and other allergens. To distinguish genuine or cross-reactive sensitization, molecular- or component-resolved diagnosis is suggested to apply in HDM-sensitized AR patients. The effect of HDM immunotherapy to treat the associated cross-reactivity in HDM-sensitized AR patients is still contradictory, and might be dependent on the degree of homology between two allergens. Furthermore, targeting tropomyosin might be a promising way to treat HDM patients with allergen cross-reactivity
基金：
national key R&D program of
China [2016YFC0905200]; the program for the Changjiang scholars and
innovative research team [IRT13082]; the national natural science foundation
of China [81630023]; Beijing municipal science and technology project
[Z181100001618002]; Beijing Municipal Administration of Hospital’s
Youth Programme [QML20180201]; the Beijing Nova Program of Science
and Technology [Z191100001119117]; and Yong top-notch talent
[2018000021223ZK12].
第一作者机构：[1]Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China[2]Beijing Key Laboratory of Nasal Disease, Beijing Institute of Otolaryngology, Beijing, China
通讯作者：
通讯机构：[1]Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China[2]Beijing Key Laboratory of Nasal Disease, Beijing Institute of Otolaryngology, Beijing, China[*1]Beijing Institute of Otolaryngology, Department of Otolaryngology Head and Neck Surgery, Capital Medical University, No.17, HouGouHuTong, DongCheng District, Beijing 100730, China
推荐引用方式(GB/T 7714)：
Zhao Limin,Zhang Yuling,Zhang Shujian,et al.The effect of immunotherapy on cross-reactivity between house dust mite and other allergens in house dust mite -sensitized patients with allergic rhinitis[J].EXPERT REVIEW OF CLINICAL IMMUNOLOGY.2021,17(9):969-975.doi:10.1080/1744666X.2021.1968834.
APA：
Zhao, Limin,Zhang, Yuling,Zhang, Shujian,Zhang, Luo&Lan, Feng.(2021).The effect of immunotherapy on cross-reactivity between house dust mite and other allergens in house dust mite -sensitized patients with allergic rhinitis.EXPERT REVIEW OF CLINICAL IMMUNOLOGY,17,(9)
MLA：
Zhao, Limin,et al."The effect of immunotherapy on cross-reactivity between house dust mite and other allergens in house dust mite -sensitized patients with allergic rhinitis".EXPERT REVIEW OF CLINICAL IMMUNOLOGY 17..9(2021):969-975
：